Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ACI-19764 in healthy participants and participants with cardiovascular risk factors
NL-OMON59928Phase 1Recruiting
- Sponsor
- AC Immune SA
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cardiac morbidity, type 2 diabetes mellitus (T2DM) and obesity comparing ACI-19764 with Placebo (2 arms). Started Jan 2026; status: recruiting.
02
Drugs
ACI-19764
03
Conditions
cardiac morbiditytype 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NL-OMON59928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59928.